Kazia Therapeutics (KZIA) Stock Price, News & Analysis

Company Overview

Kazia Therapeutics Limited operates as an oncology-focused biotechnology company. The company's lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.

Key Stats

• Today's Range: $0.85 to $0.90
• 50-Day Range: $0.88 to $3.40
• 52-Week Range: $0.85 to $15.80
• Volume: 119,678 shs
• Average Volume: 5.53 million shs
• Market Capitalization: $4.44 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $11.50
• Consensus Rating: Buy

Kazia Therapeutics Stock Analysis - MarketRank™

Kazia Therapeutics scored higher than 65% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Kazia Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Kazia Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: N/A
• Proj. Earnings Growth: N/A

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

31.68% of the float of Kazia Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Kazia Therapeutics has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Kazia Therapeutics has recently increased by 7,712.71%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Kazia Therapeutics does not currently pay a dividend.

Dividend Growth

Kazia Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

31.68% of the float of Kazia Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Kazia Therapeutics has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Kazia Therapeutics has recently increased by 7,712.71%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 4.0 / 5
• News Sentiment: N/A

News Sentiment

Kazia Therapeutics has a news sentiment score of 1.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Kazia Therapeutics this week, compared to 0 articles on an average week.

Search Interest

4 people have searched for KZIA on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.

MarketBeat Follows

1 people have added Kazia Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Kazia Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 1.00% of the stock of Kazia Therapeutics is held by insiders.

Percentage Held by Institutions

Only 30.89% of the stock of Kazia Therapeutics is held by institutions.

KZIA Stock Analysis - Frequently Asked Questions

How have KZIA shares performed this year?

Kazia Therapeutics' stock was trading at $1.77 at the start of the year. Since then, KZIA stock has decreased by 50.3% and is now trading at $0.88.
View the best growth stocks for 2025 here.

When did Kazia Therapeutics' stock split?

Shares of Kazia Therapeutics reverse split on Monday, October 28th 2024. The 1-10 reverse split was announced on Tuesday, October 15th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, October 25th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Who are Kazia Therapeutics' major shareholders?

Top institutional shareholders of Kazia Therapeutics include Barclays PLC (2.38%) and Concourse Financial Group Securities Inc.. Insiders that own company stock include Bryce Carmine, James Garner and Steven Coffey.
View institutional ownership trends.

How do I buy shares of Kazia Therapeutics?

Shares of KZIA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Kazia Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Kazia Therapeutics investors own include NVIDIA (NVDA), Adobe (ADBE), Broadcom (AVGO), Arista Networks (ANET), ServiceNow (NOW), Meta Platforms (META) and Advanced Micro Devices (AMD).

Company Calendar

• Today: 2/22/2025
• Next Earnings (Estimated): 2/24/2025
• Fiscal Year End: 6/30/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:KZIA
• Previous Symbol: ASX:KZA
• CUSIP: N/A
• CIK: 1075880
• Web: www.kaziatherapeutics.com
• Phone: (129) 472-4101
• Fax: 61-2-9476-0388
• Employees: 12
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $11.50
• High Stock Price Target: $20.00
• Low Stock Price Target: $3.00
• Potential Upside/Downside: +1,206.8%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.24
• Quick Ratio: 0.24

Sales & Book Value

• Annual Sales: $1.51 million
• Price / Sales: 2.94
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($1.97) per share
• Price / Book: -0.45

Miscellaneous

• Outstanding Shares: 5,040,000
• Free Float: 4,986,000
• Market Cap: $4.44 million
• Optionable: Optionable
• Beta: 2.11